SOLICITATION NOTICE
B -- Evaluation of the MarketScan Database for Studies of Drug-Related Cancers
- Notice Date
- 8/14/2012
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120168-LG
- Archive Date
- 9/12/2012
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Epidemiology and Biostatistics Program (EBP) plans to procure on a sole source basis services from Consolidated Research, Inc., 10490 Holman Avenue, Los Angeles, CA 90024, for an evaluation of the MarketScan Database for studies of drug-related cancers and specific assessment of prostate cancer risks associated with androgen medications. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $14.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Epidemiology and Biostatistics Program (EBP) is assessing the effect of use of specific medications and subsequent cancer risks. Since an in-depth assessment can be complex and resource consumptive, the EBP has long sought a data resource that would have sufficient information to screen for drugs that show evidence of such effects, in order to decide which ones warrant more comprehensive data collection efforts. The EBP proposes to do this by conducting a pharmacoepidemiologic study of cancer using the MarketScan database. For such a study, the EBP will investigate the risks of prostate cancer among men taking androgenic drugs (specifically testosterone). By conducting such a study the EBP will gain valuable information on a high-interest hypothesis, and at the same time learn whether the MarketScan database is or is not a good resource for this type of pharmacologic study in the future to screen for potential associations. The contractor will add DCEG as a collaborator on its pharmacologic study of unintended side-effects of use of androgen-containing medications. The contractor will then evaluate these data along with DCEG and assist in developing a specific cohort of 3 million individuals which will allow the assessment of risks of prostate cancer and heart disease following the use of androgen medications. The DCEG will work with the contractor on its analyses of heart disease risks, and the contractor will share its experience in and programs for analyzer of this database. The result will be two publication-ready manuscripts assessing two potential adverse outcomes of androgenic medication use. The MarketScan database is the only pharmacy database with linked diagnoses that is large enough (30 million subjects) and with enough longitudinal data (follow-up for 6+ years) to be useful for etiologic studies of cancer. However, no such studies have yet been done using this database (no publication in this area out of 336 publications from the database). The costs involved in access to the database and the absence of any help with understanding or analyzing it made it unlikely that the EBP could pursue its plan. Consolidated Research Inc (CRI) is a group of renowned statisticians and epidemiologists, very familiar with the database, who are in the process of developing an etiologic study of the same medications of interest to the EBP. By partnering with CRI, the EBP will gain access to the full MarketScan database, obtain a copy of the relevant subcohort of three million subjects, be able to access and use programs developed specifically to do epidemiologic analyses of the database, and receive guidance and consultation from experts in epidemiologic analysis of these data. Given CRI's current access to and experience with the MarketScan database, along with its current investigations on the same medications, it is the only known contractor that can fulfill the requirements of this project. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on August 28, 2012. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Laura Glockner, Contract Specialist at laura.glockner@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through SAM.gov. No collect calls will be accepted. Please reference solicitation number NCI-120168-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120168-LG/listing.html)
- Record
- SN02839597-W 20120816/120815001538-8002e988c3b325d881a52e0047a16537 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |